Eltrombopag  	Eltrombopag  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
idiopathic  	idiopathic  	 NNS	I-NP
( 	( 	 -LRB-	O
immune 	immune 	 JJ	O
)  	)  	 -RRB-	O
thrombocytopenic  	thrombocytopenic  	 FW	B-NP
purpura  	purpura  	 FW	I-NP
( 	( 	 -LRB-	O
ITP 	ITP 	 NNP	B-NP
)  	)  	 -RRB-	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
eltrombopag  	eltrombopag  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
adults  	adults  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
idiopathic  	idiopathic  	 NNS	I-NP
( 	( 	 -LRB-	O
immune 	immune 	 JJ	O
)  	)  	 -RRB-	O
thrombocytopenic  	thrombocytopenic  	 FW	B-NP
purpura  	purpura  	 FW	I-NP
( 	( 	 -LRB-	O
ITP 	ITP 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
( 	( 	 -LRB-	O
MS 	MS 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
ITP  	ITP  	 NNP	B-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
autoimmune  	autoimmune  	 JJ	B-NP
disorder  	disorder  	 NN	I-NP
by  	by  	 IN	O
which  	which  	 WDT	O
antibodies  	antibodies  	 NNS	B-NP
are  	are  	 VBP	O
formed  	formed  	 VBN	O
against  	against  	 IN	O
platelets  	platelets  	 NN	B-NP
with  	with  	 IN	O
annual  	annual  	 JJ	O
incidence  	incidence  	 NN	B-NP
rates  	rates  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
UK 	UK 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
USA  	USA  	 NNP	I-NP
ranging  	ranging  	 VBG	O
from  	from  	 IN	O
1.13  	1.13  	 CD	O
to  	to  	 TO	O
6.62  	6.62  	 CD	O
cases  	cases  	 NNS	O
per  	per  	 IN	O
100,000  	100,000  	 CD	O
adults 	adults 	 NNS	O
.  	.  	 .	O
Eltrombopag  	Eltrombopag  	 NNP	B-NP
increases  	increases  	 VBZ	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
platelets  	platelets  	 NN	B-NP
at  	at  	 IN	O
a  	a  	 DT	O
rate  	rate  	 NN	O
that  	that  	 IN	O
outpaces  	outpaces  	 VBG	O
their  	their  	 PRP$	O
destruction  	destruction  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
system 	system 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
has  	has  	 VBZ	O
a  	a  	 DT	O
UK  	UK  	 NNP	B-NP
marketing  	marketing  	 NN	I-NP
authorisation  	authorisation  	 NNS	I-NP
both  	both  	 CC	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
adult  	adult  	 NN	B-NP
ITP  	ITP  	 NN	I-NP
in  	in  	 IN	O
splenectomised  	splenectomised  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
who  	who  	 WP	O
are  	are  	 VBP	O
refractory  	refractory  	 VBN	O
to  	to  	 TO	O
other  	other  	 JJ	O
treatments  	treatments  	 NNS	O
and  	and  	 CC	O
as  	as  	 IN	O
a  	a  	 DT	O
second-line  	second-line  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
for  	for  	 IN	O
adult  	adult  	 JJ	O
non-splenectomised  	non-splenectomised  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
for  	for  	 IN	O
whom  	whom  	 WP	O
surgery  	surgery  	 NN	O
is  	is  	 VBZ	O
contraindicated 	contraindicated 	 VBN	O
.  	.  	 .	O
Both  	Both  	 DT	O
splenectomised  	splenectomised  	 NN	O
and  	and  	 CC	O
non-splenectomised  	non-splenectomised  	 JJ	B-NP
patient  	patient  	 NN	I-NP
groups  	groups  	 NNS	I-NP
were  	were  	 VBD	O
considered  	considered  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
analysis 	analysis 	 NN	O
.  	.  	 .	O
Two  	Two  	 CD	O
economic  	economic  	 JJ	B-NP
models  	models  	 NNS	I-NP
were  	were  	 VBD	O
presented 	presented 	 VBN	O
,  	,  	 ,	O
one  	one  	 CD	O
for  	for  	 IN	O
a  	a  	 DT	O
watch-and-rescue  	watch-and-rescue  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
scenario  	scenario  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
second  	second  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
more  	more  	 RBR	O
severe  	severe  	 JJ	O
ITP 	ITP 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
was  	was  	 VBD	O
sourced  	sourced  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
relatively  	relatively  	 RB	O
high-quality  	high-quality  	 JJ	B-NP
RAISE  	RAISE  	 NNP	I-NP
[ 	[ 	 -LRB-	O
RAndomized  	RAndomized  	 FW	O
placebo-controlled  	placebo-controlled  	 FW	O
Idiopathic  	Idiopathic  	 FW	B-NP
thrombocytopenic  	thrombocytopenic  	 FW	I-NP
purpura  	purpura  	 FW	I-NP
( 	( 	 -LRB-	O
ITP 	ITP 	 NNP	B-NP
)  	)  	 -RRB-	O
Study  	Study  	 NN	O
with  	with  	 IN	O
Eltrombopag 	Eltrombopag 	 NNP	B-NP
]  	]  	 -RRB-	O
randomised  	randomised  	 VBZ	O
controlled  	controlled  	 VBN	B-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
indicated  	indicated  	 VBD	O
a  	a  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
favour  	favour  	 NN	O
of  	of  	 IN	O
eltrombopag  	eltrombopag  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
placebo  	placebo  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
odds  	odds  	 NNS	O
of  	of  	 IN	O
achieving  	achieving  	 VBG	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
of  	of  	 IN	I-NP
a  	a  	 DT	I-NP
platelet  	platelet  	 JJ	I-NP
count  	count  	 NN	I-NP
of  	of  	 IN	O
between  	between  	 IN	O
50  	50  	 CD	O
and  	and  	 CC	O
400  	400  	 CD	O
×  	×  	 CD	O
109 	109 	 CD	O
/ 	/ 	 CD	O
l  	l  	 NN	O
during  	during  	 IN	O
the  	the  	 DT	O
6-month  	6-month  	 JJ	O
treatment  	treatment  	 NN	B-NP
period  	period  	 NN	I-NP
( 	( 	 -LRB-	O
odds  	odds  	 JJ	B-NP
ratio  	ratio  	 NN	I-NP
8.2 	8.2 	 CD	O
,  	,  	 ,	O
99 	99 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 VBD	I-NP
3.6  	3.6  	 CD	O
to  	to  	 TO	O
18.7 	18.7 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
eltrombopag  	eltrombopag  	 JJ	B-NP
group 	group 	 NN	I-NP
,  	,  	 ,	O
50 	50 	 CD	O
/ 	/ 	 CD	O
83  	83  	 CD	O
( 	( 	 -LRB-	O
60 	60 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
non-splenectomised  	non-splenectomised  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
18 	18 	 CD	O
/ 	/ 	 CD	O
49  	49  	 CD	O
( 	( 	 -LRB-	O
37 	37 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
splenectomised  	splenectomised  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
achieved  	achieved  	 VBD	O
this  	this  	 DT	O
outcome 	outcome 	 NN	O
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
duration  	duration  	 NN	I-NP
of  	of  	 IN	O
response  	response  	 NN	O
for  	for  	 IN	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
was  	was  	 VBD	O
10.9  	10.9  	 CD	O
weeks  	weeks  	 NNS	O
( 	( 	 -LRB-	O
splenectomised  	splenectomised  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
6  	6  	 CD	O
weeks  	weeks  	 NNS	O
and  	and  	 CC	O
non-splenectomised  	non-splenectomised  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
13.4  	13.4  	 CD	O
weeks 	weeks 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
eltrombopag  	eltrombopag  	 VBG	O
required  	required  	 VBN	O
less  	less  	 JJR	O
rescue  	rescue  	 NN	B-NP
medication  	medication  	 NN	I-NP
and  	and  	 CC	O
had  	had  	 VBD	O
lower  	lower  	 JJR	O
odds  	odds  	 NNS	O
of  	of  	 IN	O
bleeding  	bleeding  	 VBG	B-NP
events  	events  	 NNS	I-NP
than  	than  	 IN	O
placebo-treated  	placebo-treated  	 JJ	O
subjects  	subjects  	 NNS	B-NP
in  	in  	 IN	O
both  	both  	 DT	O
patient  	patient  	 JJ	O
groups 	groups 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
watch-and-rescue  	watch-and-rescue  	 JJ	B-NP
economic  	economic  	 JJ	I-NP
model 	model 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
found  	found  	 VBD	O
that  	that  	 DT	O
substantial  	substantial  	 JJ	O
reductions  	reductions  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
cost  	cost  	 NN	O
of  	of  	 IN	O
eltrombopag  	eltrombopag  	 NNS	B-NP
are  	are  	 VBP	O
needed  	needed  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
fall  	fall  	 VB	O
below  	below  	 IN	O
£  	£  	 CD	O
30,000 	30,000 	 CD	O
.  	.  	 .	O
Further  	Further  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
found  	found  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
ICER  	ICER  	 NNP	B-NP
varied  	varied  	 VBD	O
from  	from  	 IN	O
£33,561  	£33,561  	 CD	O
to  	to  	 TO	O
£  	£  	 FW	O
103,500  	103,500  	 FW	O
per  	per  	 FW	O
quality-adjusted  	quality-adjusted  	 FW	B-NP
life-year  	life-year  	 FW	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
splenectomised 	splenectomised 	 LS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
from  	from  	 IN	O
£  	£  	 CD	O
39,657  	39,657  	 CD	O
to  	to  	 TO	O
£  	£  	 CD	O
150,245  	150,245  	 CD	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
( 	( 	 -LRB-	O
non-splenectomised 	non-splenectomised 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Other  	Other  	 JJ	O
than  	than  	 IN	O
bleeding 	bleeding 	 NN	O
,  	,  	 ,	O
no  	no  	 DT	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
modelled 	modelled 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
relation  	relation  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	B-NP
model 	model 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
found  	found  	 VBD	O
that  	that  	 IN	O
using  	using  	 VBG	O
non-randomised  	non-randomised  	 JJ	B-NP
non-comparative  	non-comparative  	 JJ	I-NP
data  	data  	 NNS	I-NP
may  	may  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
biased  	biased  	 JJ	O
estimates  	estimates  	 NNS	O
of  	of  	 IN	O
unknown  	unknown  	 JJ	O
magnitude  	magnitude  	 NN	O
and  	and  	 CC	O
direction 	direction 	 NN	O
.  	.  	 .	O
None  	None  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	B-NP
sequences  	sequences  	 VBZ	I-NP
resulted  	resulted  	 VBN	O
in  	in  	 IN	O
an  	an  	 DT	O
ICER  	ICER  	 NNP	B-NP
approaching  	approaching  	 VBG	O
the  	the  	 DT	O
recommended  	recommended  	 JJ	O
threshold  	threshold  	 NN	O
of  	of  	 IN	O
£  	£  	 CD	O
30,000 	30,000 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
base-case  	base-case  	 JJ	B-NP
results 	results 	 NNS	I-NP
,  	,  	 ,	O
using  	using  	 VBG	O
a  	a  	 DT	O
2-year  	2-year  	 JJ	O
time  	time  	 NN	B-NP
horizon  	horizon  	 NN	I-NP
and  	and  	 CC	O
prescribing  	prescribing  	 JJ	O
eltrombopag  	eltrombopag  	 NN	B-NP
as  	as  	 IN	O
second-line  	second-line  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
post  	post  	 NN	I-NP
rituximab 	rituximab 	 NN	I-NP
,  	,  	 ,	O
were  	were  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
favourable  	favourable  	 VBN	O
towards  	towards  	 IN	O
eltrombopag 	eltrombopag 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
MS  	MS  	 NNP	B-NP
and  	and  	 CC	O
additional  	additional  	 JJ	O
ERG  	ERG  	 NNP	O
work 	work 	 NN	O
,  	,  	 ,	O
eltrombopag  	eltrombopag  	 NN	B-NP
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
a  	a  	 DT	O
safe  	safe  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
ITP  	ITP  	 NNP	B-NP
( 	( 	 -LRB-	O
although  	although  	 IN	O
long-term  	long-term  	 JJ	O
follow-up  	follow-up  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
are  	are  	 VBP	O
awaited 	awaited 	 VBN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
has  	has  	 VBZ	O
short-term  	short-term  	 JJ	O
efficacy 	efficacy 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
robust  	robust  	 JJ	O
evidence  	evidence  	 NN	O
on  	on  	 IN	O
long-term  	long-term  	 JJ	O
efficacy  	efficacy  	 NN	O
or  	or  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
eltrombopag 	eltrombopag 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
robust  	robust  	 JJ	O
direct  	direct  	 JJ	O
evidence  	evidence  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	O
eltrombopag  	eltrombopag  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
other  	other  	 JJ	O
relevant  	relevant  	 JJ	O
comparators 	comparators 	 NN	B-NP
.  	.  	 .	O
NICE  	NICE  	 JJ	O
did  	did  	 VBD	O
not  	not  	 RB	O
recommend  	recommend  	 VB	O
eltrombopag  	eltrombopag  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
ITP  	ITP  	 NN	I-NP
within  	within  	 IN	O
its  	its  	 PRP$	O
marketing  	marketing  	 NN	B-NP
authorisation  	authorisation  	 NN	I-NP
for  	for  	 IN	O
splenectomised  	splenectomised  	 NN	O
or  	or  	 CC	O
non-splenectomised  	non-splenectomised  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
